ProfileHIT’s vascular system screening against COVID-19
ProfileHIT contributes to the global effort against COVID-19 pandemic with a screening of 700 FDA drugs library using our vascular system. ProfileHIT’s screening has been performed on more than 40 parameters including the receptor for the SARS-CoV-2 viral entry, the angiotensin converting enzyme-2 (ACE-2). Based on the preliminary report from the RECOVERY trial, the COVID-19 Treatment Guidelines Panel (the Panel) recommends the use of dexamethasone or alternative glucocorticoids such as prednisone, methylprednisolone, or hydrocortisone. Other drugs tested against COVID-19 have been included in our screening such as chloroquine, hydroxychloroquine and a combination of Azithromycin (AZT) and hydroxychloroquine. A summary of our results is presented including all these drugs.
Dexamethasone cumulates ACE2 receptor inhibition and vascular protection regarding coagulation (TM and EPCR upregulation) or complement regulation proteins (CD55 and CD59 upregulation). Our screening confirms that only a multiparametric approach can help us to find COVID19 candidates. Chemical compounds alone or in combination with immunotherapies must be considered.
Our R&D team believes since the beginning of the pandemic that vascular functions are involved in the pathology and now many research articles are published in this field. A non-exhausted list of publications on this topic can be found below.
Drug repurposing is one of the faster way with vaccines to protect people against COVID-19, companies or public health authority interested in our strategy or willing to know more about our study are invited to contact us: email@example.com.